A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation Mark H. Kirschbaum,

Slides:

Advertisements

Similar presentations

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Advertisements

Serial Profile of Vitamins and Trace Elements during the Acute Phase of Allogeneic Stem Cell Transplantation Yasuhito Nannya, Akihito Shinohara, Motoshi.

Combination of Linear Accelerator–Based Intensity-Modulated Total Marrow Irradiation and Myeloablative Fludarabine/Busulfan: A Phase I Study Pritesh.

How to Treat MDS without Stem Cell Transplantation

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation David Stephen Shulman, Wendy B. London, Dongjing.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Intravenous Busulfan-Cyclophosphamide as a Preparative Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Acute.

Clofarabine and High-Dose Melphalan as Reduced Intensity Conditioning in Adults with High-Risk Leukemia/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation

Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation Joseph H. Antin, Eva C. Guinan,

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Up-regulation of NK Cell Activating Receptors Following Allogeneic Hematopoietic Stem Cell Transplantation under a Lymphodepleting Reduced Intensity Regimen.

Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology

Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation in Myelofibrosis

Standardized CD3+ Cell Dose for Allogeneic Peripheral Blood Stem Cell Transplant (PBSCT): An Interim Analysis Muhammad Omer Jamil, MD, Ayman Saad, MD,

Feasible Outcomes of T Cell–Replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome

Sabina Kersting, Leo F. Verdonck

Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.

Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia Vivian.

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Increased Programmed Death-1 Molecule Expression in Cytomegalovirus Disease and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma Robert Chen, Joycelynne.

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in.

Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia Anthony Stein,

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic.

Does Adding Zevalin® to Reduced Intensity Regimen (RIC) of Fludarabine and Melphalan Improve Outcome of Patients with Relapsed/Refractory B-Cell Lymphoma.

Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation Jan Storek,

Cell-Based Therapy Using Umbilical Cord Blood for Novel Indications in Regenerative Therapy and Immune Modulation: An Updated Systematic Scoping Review.

B Cells and Transplantation: An Educational Resource

Reduced-Intensity Conditioning followed by Peripheral Blood Stem Cell Transplantation for Adult Patients with High-Risk Acute Lymphoblastic Leukemia

Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I- Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients.

Cellular Immune Reconstitution and Its Impact on Clinical Outcome in Children with β Thalassemia Major Undergoing a Matched Related Myeloablative Allogeneic.

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Impact of Graft Cell Dose on Transplant Outcomes following Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Higher CD34+ Cell Doses.

High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphoma (PTCL): Analysis of Prognostic Factors Auayporn Nademanee,

Efficacy of CD34+ Stem Cell Dose in Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation after Total Body Irradiation Anurag K.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Analysis of Hematopoietic Cell Transplants Using Plasma-Depleted Cord Blood Products That Are Not Red Blood Cell Reduced Robert Chow, Auayporn Nademanee,

A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory.

Akiko M. Saito, Corey Cutler, David Zahrieh, Robert J

Pauline Damien, David S. Allan

What is quality in a transplant program?

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Non-CD34+ Cells, Especially CD8+ Cytotoxic T Cells and CD56+ Natural Killer Cells, Rather Than CD34 Cells, Predict Early Engraftment and Better Transplantation.

Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV? Marie von Lilienfeld-Toal, MD, Maria Gilleece,

Blood and Marrow Transplant Handbook

A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome Peggy A. Wu,

Varicella-Zoster Virus Disease Is More Frequent after Cord Blood Than after Bone Marrow Transplantation Kristel Vandenbosch, Philippe Ovetchkine, Martin.

Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study Luis F.

Reconstitution of T Cell Subset Repertoire Diversity following Multiple Antigen- Mismatched Bone Marrow Transplantation Thea M. Friedman, Olga Azhipa,

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Megadose CD34+ Cell Grafts Improve Recovery of T Cell Engraftment but not B Cell Immunity in Patients with Severe Combined Immunodeficiency Disease Undergoing.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Optimal Donor Selection: Beyond HLA

Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective.

Presentation transcript:

A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation Mark H. Kirschbaum, Anthony S. Stein, Leslie Popplewell, Maria Delioukina, Robert Chen, Ryotaro Nakamura, David Snyder, Joel Conrad, Simon F. Lacey, Paul Frankel, Andrew Dagis, Auayporn Nademanee, Stephen J. Forman Biology of Blood and Marrow Transplantation Volume 18, Issue 3, Pages 432-440 (March 2012) DOI: 10.1016/j.bbmt.2011.07.017 Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Treatment schema. Treatments are shown on the timeline spanning the days before stem cell infusion on day 0. Mel, melphalan. Biology of Blood and Marrow Transplantation 2012 18, 432-440DOI: (10.1016/j.bbmt.2011.07.017) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Reconstitution of immune cell subsets. Mean cell numbers are plotted for 15 patients. Error bars indicate standard error. Subsets were defined as follows: CD4 T cells (CD3+, CD45+, CD4+), CD8 T cells (CD3+, CD45+, CD8+), NK cells (CD45+, CD3−, CD16+, CD56+), B cells (CD45+, CD5−, CD19+). Dotted lines represent the upper and lower ranges of normal values. Biology of Blood and Marrow Transplantation 2012 18, 432-440DOI: (10.1016/j.bbmt.2011.07.017) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 OS and EFS estimates for the 12 patients at dose level 2 (clofarabine 40 mg/m2 and melphalan 100 mg/m2), who had a median follow-up time of 16.8 months. Biology of Blood and Marrow Transplantation 2012 18, 432-440DOI: (10.1016/j.bbmt.2011.07.017) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions